

# Views from our Medical Director



Collapsing glomerulopathy (CG) was first described in the 1980's and is associated with a marked dysregulation of podocytes that has been described as a “transdifferentiation” towards a macrophage-like cell. This lesion usually leads to a rapid loss of kidney function and is often resistant to therapy. First described in association with HIV infection (HIV-associated nephropathy, or HIVAN), it has subsequently been seen with other types of viral and mycobacterial infection, malignancy, autoimmune diseases, and drug exposure.

Heterozygous polymorphisms in the APOL1 allele may be seen in up to 13% of Americans with African ancestry. Two gain-of-function mutations, G1 and G2, have been identified and individuals who are homozygous for a gain-of-function polymorphism are at markedly increased risk for chronic kidney disease (CKD.) In particular, the variants seem to be highly associated with focal-segmental glomerulosclerosis (FSGS,) HIVAN, and lupus glomerulonephritis with collapsing features. The mechanism by which these polymorphisms cause kidney disease is unclear but there are two leading hypotheses. First, the risk variants may create pores in kidney cell membranes in a manner similar to what is seen with tryposomal organelles; in fact, the APOL1 polymorphisms seem to be protective against tryposomal disease, which explains their prevalence in endemic areas such as West Africa. Second, it has been postulated that the variants lead to mitochondrial dysfunction and injury. APOL1 variants seem to largely explain the higher rate of CKD seen in the African-American population, although they also contribute to the incidence of CKD around the world including in countries in which many people are of mixed ancestry such as Brazil. The observation that many if not most patients with homozygous variants do not experience CKD suggests that other environmental or infectious factors remain important.

## CASE STUDY

This case report presents a patient with mild kidney disease not associated with albuminuria. After a SARS-CoV-2 infection she experienced acute kidney injury with heavy proteinuria and CG on what was described as a “high-risk” biopsy. Subsequent genetic testing showed that she had both the G1 and G2 APOL1 variants. AKI in association with COVID-related systemic inflammatory response syndrome (SIRS) as well as direct viral infection of renal tubules has been described. In fact, AKI may be seen in almost half of patients admitted to the hospital for COVID-19. **This case is one of several demonstrating a correlation with SARS-CoV-2 infection and CG and advances our understanding of the pattern of renal injury seen due to the pandemic.**

This case illustrates the clinical utility of genetic testing for APOL1 variants. Had this information been available earlier in her course she may have been able to avoid a high-risk biopsy. Further, the identification of these variants may inform their prognosis and treatment option. For example, people with hypertension and homozygous APOL1 variants may respond better to angiotensin-converting enzyme inhibitors (ACE-I.)

Thus, it seems that during the pandemic and going forward, more wide-spread genetics testing to identify those with APOL1 risk variants is imperative.



**Phil Gauthier, MD MBA**  
 Medical Director, Organ Transplantation  
 Natera, Inc  
[pgauthier@natera.com](mailto:pgauthier@natera.com)

## REFERENCES:

1. Albasqami M, Soos T, Barisone L, et al. Collapsing glomerulopathy. J Am Soc Nephrol 2006; 17(10): 2854-2863; DOI: <https://doi.org/10.1681/ASN.2006030225>
2. Friedman DJ and Pollack MR. APOL1 nephropathy: From genetics to clinical applications. CJASN 2021; 16; doi: <https://doi.org/10.2215/CJN.15161219>
3. Diabisi OA, Zhang JY, VerPlank L, et al. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci U S A 113: 830-837, 2016
4. Mal,ChouJW, Snipes JA,Bharadwaj MS,et al. APOL1 renal-risk variants induce mitochondrial dysfunction. J Am Soc Nephrol 28: 1093-1105, 2017
5. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011 Nov;22(11):2129-37